Evidence map›Paper›PMID 36444213›Full record

ArticleInfection and drug resistance2022

Ceftolozane/Tazobactam Activity Against Drug-Resistant

Michael Pfaller, Dee Shortridge, Wei-Ting Chen, Helio Sader, Mariana Castanheira

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026
    Review
  3. New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Lung Transplantation: Clinical Evidence, Safety, and PK/PD Properties.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Michael PfallerJMI Laboratories, North Liberty, IA, USA.
Dee ShortridgeJMI Laboratories, North Liberty, IA, USA.
Wei-Ting ChenMerck & Co., Inc, Kenilworth, NJ, USA.
Helio SaderJMI Laboratories, North Liberty, IA, USA.
Mariana CastanheiraJMI Laboratories, North Liberty, IA, USA.
JMI Laboratories · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USUniversity of Iowa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against Methods: A total of 2038 Gram-negative organisms (376 Results: Ceftolozane/tazobactam was the most potent (MIC Conclusion: Ceftolozane/tazobactam was the most active β-lactam agent tested against

Indexed as

Asiaceftolozane/tazobactamdrug resistanceEnterobacteralesP. aeruginosasurveillance

Identifiers

PMID36444213
PMCPMC9700433
OpenAlexW4309754201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.